Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD Cosentyx® - IL-17A inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04209205 INVIGORATE-2 (CAIN457P12302) Psoriatic Arthritis (PSA) Phase 3 380 The proportion of subjects achieving American College of Rheumatology 50 (ACR50) response criteria Secukinumab intravenous (i.v.) regimen Placebo intravenous (i.v.) regimen Patients with active psoriatic arthritis (PSA) despite current or previous NSAID, DMARD and/or anti-TNF therapy Target Patients Read-out Milesstone(s) H2-2021 (Actual) Publication 2023 NCT04300296 PRELUDE (CAIN457S12201) Lichen Planus Phase 2 108 Proportion of patients achieving Investigator's Global Assessment (IGA 0/1) score at 16 weeks +30% delta vs placebo Secukinumab 300 mg s.c. Placebo s.c. Adult patients with biopsy-proven lichen planus not adequately controlled by topical therapies 2022 TBD 77 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation